Evolution of therapeutic management of patients with ANCA associated vasculitis in France after licensing Rituximab use

Abstract Introduction In 2013, rituximab was approved in France for the treatment of ANCA-associated vasculitis (AAV). The aim of the study was to compare the treatment and health events of adult incident patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), includ...

Full description

Bibliographic Details

Published in:	BMC Rheumatology
Main Authors:	Cécile-Audrey Durel, Eric Simon Thervet, Dominique Chauveau, Aurélie Schmidt, Benjamin Terrier, Pierre M Bataille
Format:	Article
Language:	English
Published:	BMC 2024-04-01
Subjects:	Antineutrophil cytoplasmic antibody-associated vasculitides Systemic vasculitis
Online Access:	https://doi.org/10.1186/s41927-024-00385-8